First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

BACKGROUND: Nucleos(t)ide analog (NA) in combination with peginterferon (PegIFN) therapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) shows better effectiveness than NA monotherapy in hepatitis B surface antigen loss, termed “functional cure,” based on previous p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xue-Ru, Liu, Zhi-Hong, Liu, Jing, Liu, Yuan-Yuan, Xie, Li, Tao, Li-Bo, Jia, Ji-Dong, Cui, Fu-Qiang, Zhuang, Gui-Hua, Hou, Jin-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819033/
https://www.ncbi.nlm.nih.gov/pubmed/31567376
http://dx.doi.org/10.1097/CM9.0000000000000445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819033/
https://www.ncbi.nlm.nih.gov/pubmed/31567376
http://dx.doi.org/10.1097/CM9.0000000000000445

Ejemplares similares